Phillip Chan, chief executive of Cytosorbents, has purchased £104,897 worth of company stock, according to a regulatory filing. The transaction, executed on 18 March 2025, saw Chan acquire 100,000 ordinary shares at an average price of $1.04897 each. The purchase was made through an open-market trade and was reported to the US Securities and Exchange Commission.
Cytosorbents, a US-based medical technology company specialising in blood purification devices, has seen its share price decline significantly over the past twelve months. The stock, which trades on the Nasdaq, has lost more than 40% of its value since March 2024, reflecting broader headwinds in the medtech sector and ongoing concerns about the company's revenue growth trajectory. The company’s flagship product, CytoSorb, is used to treat cytokine storms in critically ill patients, but adoption has been uneven across international markets.
Insider purchases are often viewed by investors as a signal of management's confidence in the firm's prospects. However, analysts caution that a single transaction, particularly one of this size, should not be taken as a definitive indicator of near-term performance. “While insider buying can be a positive sign, it is important to consider the broader context,” said a healthcare analyst at a London-based brokerage. “Cytosorbents faces significant commercial hurdles, including regulatory scrutiny and competition from alternative therapies.”
For UK investors and pension funds with exposure to US medtech stocks, the purchase may offer some reassurance amid a volatile period for the sector. The FTSE 100 has itself been under pressure in recent weeks, with the index closing at 7,642.3 points on Tuesday, down 0.6% on the day. Defensive sectors such as healthcare have been relatively resilient, but small-cap medtech names remain highly sensitive to news flow and earnings updates.
The transaction comes ahead of Cytosorbents' next quarterly earnings report, expected in early May. Investors will be watching for any updates on sales of CytoSorb in Europe and the US, as well as progress on new product approvals. The company has previously guided for modest revenue growth in 2025, but achieving that target will depend on expanding hospital contracts and securing reimbursement in key markets.